FXPOI: Mechanisms and Modifiers
FXPOI:机制和修改器
基本信息
- 批准号:10271295
- 负责人:
- 金额:$ 56.01万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-25 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:5&apos Untranslated RegionsAddressAgeAllelesAnimal ModelBinding ProteinsBiologicalBone DensityCGG repeatCandidate Disease GeneCellsChildCholesterolClinicalCoronary heart diseaseDNADNA ResequencingDataData SetDefectDevelopmentDiagnosisDiseaseEmotional StressEndotheliumEstrogensEtiologyFMR1FXTASFamilyFertilityFractureFragile X PremutationFragile X SyndromeGenesGeneticGenotypeGoalsHealthHumanImpairmentIntellectual functioning disabilityKnowledgeLengthLinkLongevityMedical HistoryMenstruationMessenger RNAModelingMolecularMusMutationOocytesOsteoporosisOutcomeOvarianOvaryPathogenicityPathway interactionsPenetrancePhenotypePopulationRNARecordsReproductive HistoryResearch PersonnelResourcesRiskRisk FactorsRoleSeriesSeveritiesTargeted ResequencingTestingTimeTissue-Specific Gene ExpressionToxic effectTranscriptTranslatingTranslationsWomanWorkautism spectrum disorderbasebody systemcell typeclinically significantcohortcombinatorialearly onseteffective interventionexperiencefamily buildinggenetic architecturegenome sequencinggranulosa cellhuman modelimprovedinduced pluripotent stem cellinnovationinsightmortalitymouse modelmultidisciplinarynoveloffspringovarian dysfunctionphenotypic datapolyglycinepolypeptideprimary ovarian insufficiencyreproductivesingle-cell RNA sequencingsteroid hormonesubfertilitysynergismtherapeutic targettoolwhole genome
项目摘要
Project Summary
Up to an estimated 1 in 151 women carry a fragile X premutation allele, impacting over one million women in the
US. Women with a premutation are at risk of having a child with fragile X syndrome (FXS), the most common
genetic form of intellectual and developmental disability and autism spectrum disorder. These women are also
at risk for fragile X-associated primary ovarian insufficiency (FXPOI), with 20-30% experiencing cessation of
menses prior to age 40. Reduced fertility is the most significant consequence of FXPOI. Other health
consequences due to early estrogen deficiency include low bone density, early-onset osteoporosis and fractures,
impaired endothelial function, early-onset coronary heart disease, and increased overall mortality. Women with
a premutation are a prevalent, yet understudied population. They are at the center of families diagnosed with
fragile X-associated disorders. The focus of this proposal is to identify the modifiers and mechanisms of FXPOI.
Current data support two non-mutually exclusive molecular pathogenic mechanisms associated with the long
premutation CGG repeat track in the FMR1 transcript (rCGG): 1) expanded rCGG transcripts potentially
sequester essential proteins that bind to the rCGGs and 2) the premutation rCGG induces repeat-associated
non-AUG (RAN) translation within the 5' UTR of FMR1 mRNA, producing polypeptides that may be toxic. With
respect to modifiers of severity, we showed previously that the premutation repeat length explains only ~13% of
the risk to develop FXPOI; thus, additional modifiers of must exist. Our strong preliminary studies support the
following hypothesis: FXPOI is a multifactorial disorder that results from the molecular consequence of
premutation-size rCGGs, primarily the toxic effect of RAN translation products, on the background of modifying
genes that exacerbate the severity of FXPOI. We will test this hypothesis using a series of premutation mouse
and human models and tools generated by investigators of the Center. The goal will be to test the roles of RNA
sequestration and RAN-translation. In addition, we will build on our whole genome sequencing results and on
other novel datasets generated by Center investigators to identify and screen candidate modifying genes in our
large cohort of premutation and non-carriers on whom we have collected rich phenotype data. This unique
Center, focused on fragile X premutation disorders, has gathered a multi-disciplinary collaborative team who
have significant track records in the fragile X field. Their expertise provides novel resources and tools to address
critical knowledge gaps related to the risk factors and pathways associated with FXPOI and other premutation-
associated disorders. Filling these gaps will guide the implementation of timely and effective interventions.
项目摘要
据估计,每151名妇女中就有1名携带脆性X前突变等位基因,影响了100多万名妇女。
我们有前突变的妇女有患脆性X综合征(FXS)的风险,这是最常见的
遗传形式的智力和发育残疾以及自闭症谱系障碍。这些女性也是
易患脆性X相关的原发性卵巢功能不全(FXPOI),20-30%的患者停止使用
40岁之前月经。生育能力降低是FXPOI最重要的后果。其他健康
早期雌激素缺乏的后果包括低骨密度,早发性骨质疏松症和骨折,
内皮功能受损、早发冠心病和总体死亡率增加。妇女
前突变是一个普遍的,但研究不足的群体。他们是被诊断为
脆性X相关疾病该提案的重点是确定FXPOI的修饰剂和机制。
目前的数据支持两个非相互排斥的分子致病机制与长期
FMR 1转录本(rCGG)中的前突变CGG重复轨道:1)扩增的rCGG转录本可能
螯合与rCGG结合的必需蛋白,2)前突变rCGG诱导重复相关的
在FMR 1 mRNA的5' UTR内的非AUG(RAN)翻译,产生可能有毒的多肽。与
关于严重程度的修饰语,我们先前表明,前突变重复序列长度仅解释了~13%的
开发FXPOI的风险;因此,必须存在额外的修改器。我们强大的初步研究支持
以下假设:FXPOI是一种多因素疾病,由以下因素的分子后果引起:
前突变大小的rCGG,主要是RAN翻译产物的毒性作用,在修饰的背景下,
这些基因加剧了FXPOI的严重性。我们将使用一系列前突变小鼠来检验这一假设。
以及中心研究人员制作的人体模型和工具。目标是测试RNA的作用
螯合和RAN翻译。此外,我们将建立在我们的全基因组测序结果和
中心研究人员生成的其他新数据集,以识别和筛选我们的候选修饰基因。
我们收集了大量的前突变和非携带者的表型数据。这种独特
中心,专注于脆性X前突变障碍,已经聚集了一个多学科的合作团队,
在易碎品领域有着良好的记录他们的专业知识提供了新的资源和工具,
与FXPOI和其他前突变相关的风险因素和途径相关的关键知识差距-
相关疾病。填补这些空白将指导及时和有效的干预措施的实施。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Emily Graves Allen其他文献
Emily Graves Allen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Emily Graves Allen', 18)}}的其他基金
Metabolic Dysregulation in FXTAS Pathogenesis
FXTAS 发病机制中的代谢失调
- 批准号:
10224940 - 财政年份:2020
- 资助金额:
$ 56.01万 - 项目类别:
Metabolic Dysregulation in FXTAS Pathogenesis
FXTAS 发病机制中的代谢失调
- 批准号:
10057606 - 财政年份:2020
- 资助金额:
$ 56.01万 - 项目类别:
相似海外基金
Impact of alternative polyadenylation of 3'-untranslated regions in the PI3K/AKT cascade on microRNA
PI3K/AKT 级联中 3-非翻译区的替代多聚腺苷酸化对 microRNA 的影响
- 批准号:
573541-2022 - 财政年份:2022
- 资助金额:
$ 56.01万 - 项目类别:
University Undergraduate Student Research Awards
How do untranslated regions of cannabinoid receptor type 1 mRNA determine receptor subcellular localisation and function?
1 型大麻素受体 mRNA 的非翻译区如何决定受体亚细胞定位和功能?
- 批准号:
2744317 - 财政年份:2022
- 资助金额:
$ 56.01万 - 项目类别:
Studentship
MICA:Synthetic untranslated regions for direct delivery of therapeutic mRNAs
MICA:用于直接递送治疗性 mRNA 的合成非翻译区
- 批准号:
MR/V010948/1 - 财政年份:2021
- 资助金额:
$ 56.01万 - 项目类别:
Research Grant
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
- 批准号:
10019570 - 财政年份:2019
- 资助金额:
$ 56.01万 - 项目类别:
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
- 批准号:
10223370 - 财政年份:2019
- 资助金额:
$ 56.01万 - 项目类别:
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
- 批准号:
10455108 - 财政年份:2019
- 资助金额:
$ 56.01万 - 项目类别:
Synergistic microRNA-binding sites, and 3' untranslated regions: a dialogue of silence
协同的 microRNA 结合位点和 3 非翻译区:沉默的对话
- 批准号:
255762 - 财政年份:2012
- 资助金额:
$ 56.01万 - 项目类别:
Operating Grants
Analysis of long untranslated regions in Nipah virus genome
尼帕病毒基因组长非翻译区分析
- 批准号:
20790351 - 财政年份:2008
- 资助金额:
$ 56.01万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Search for mRNA elements involved in the compatibility between 5' untranslated regions and coding regions in chloroplast translation
寻找参与叶绿体翻译中 5 非翻译区和编码区之间兼容性的 mRNA 元件
- 批准号:
19370021 - 财政年份:2007
- 资助金额:
$ 56.01万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Post-transcriptional Regulation of PPAR-g Expression by 5'-Untranslated Regions
5-非翻译区对 PPAR-g 表达的转录后调控
- 批准号:
7131841 - 财政年份:2006
- 资助金额:
$ 56.01万 - 项目类别: